References
- McKusick VA, Ruddle FH. A new discipline, a new name, a new journal. Genomics 1(1), 1–2 (1987).
- Perspective: genomics: structural and functional studies of genomes. Genomics 45(2), 244–249 (1997).
- Baltimore D. Our genome unveiled. Nature 409, 814–818 (2001).
- Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 405, 827–836 (2000).
- Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur. J. Cancer 40(17), 2623–2632 (2004).
- Smith KD, Bolouri H. Dissecting innate immune responses with the tools of systems biology. Curr. Opin. Immunol. 17, 49–54 (2005).
- Rammensee H, Bachmann J, Emmerich N, Bacho OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213–219 (1999).
- Peters B, Tong W, Sidney J, Sette A, Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-1 molecules. Bioinformatics 19, 1765–1772 (2003).
- Wang R. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. 188(1), 65–80 (2002).
- Rosenberg SA, Zhai Y, Yang JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl Cancer Inst. 90, 1894–1900 (1998).
- Dillman R, Selvan S, Schiltz P et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother. Radiopharm. 19(5), 658–665 (2004).
- Burack WR, Lee KH, Holdorf AD, Dustin ML, Shaw AS. Cutting edge: quantitative imaging of raft accumulation in the immunological synapse. J. Immunol. 169, 2837–2841 (2002).
- Prakken B, Wauben M, Genini D et al. Artificial antigen-presenting cells as a tool to exploit the immune synapse. Nature Med. 6(12), 1406–1410 (2000).
- Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U et al. Competition of peptide-MHC class I tetrameric complexes with antiCD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 41, 321–328 (2000).
- Cope AP, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr. Opin. Immun. 16, 780–786 (2004).
- Gregorek H, Dzierzanowska-Fangrat K, Woynarwoski M et al. Persistence of HBVDNA in children with chronic hepatitis B who seroconverted to antiHBs antibodies after interferon-α therapy: correlation with specific IgG subclass responses to HBsAg. J. Hepatol. 42, 486–490 (2005).
- Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann. Surg. Oncol. 11, 892–899 (2004).
- Criscione LG, St Clair EW. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr. Opin. Rheumatol. 14, 204–211 (2002).
- Prakken BJ, Samodal R, Le TD et al. Epitope-specific immunotherapy induces immune deviation of pro-inflammatory T-cells in rheumatoid arthritis. Proc. Natl Acad. Sci USA 101(12), 4228–4233 (2004).